Olomorasib with pembrolizumab in the first-line showed a 77% overall response rate in patients with KRAS G12C–mutated ...

Binod Dhakal, MD, MS, discusses some of the challenges often seen in the myeloma space, particularly those with lenalidomide-refractory multiple myeloma.

A new drug combination, talquetamab and teclistamab, shows promising results in treating patients with heavily pretreated ...

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the phase 3 CEPHEUS trial of daratumumab with bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma.

Camrelizumab increased the 3-year event-free survival rate vs standard of care from 77.3% to 86.9%, translating to a 44% ...

Panelists discuss how updates from KEYNOTE-522 at ESMO 2024 revealed important data on overall survival and event-free survival outcomes.

Panelists discuss how the NATALEE study at ESMO 2024 presented updates on primary, secondary, and exploratory endpoints for evaluating a new cancer treatment.

The FDA’s Oncologic Drug Advisory Committee voted against the use of checkpoint inhibitors in esophageal cancer with PD-L1 ...